An immunotherapy guide constructed by cGAS-STING signature for breast cancer and the biofunction validation of the pivotal gene HOXC13 via in vitro experiments
Our study implies that HOXC13 is a potential therapy target for BRCA immunotherapy and 11-gene signature is a potential tool for clinical evaluation of anti-PD1/PDL1 therapy efficacy.
Authors
- Zhen Gu (ORCID: https://orcid.org/0000-0003-2947-4456)
- Zhen-ling Dai
- Jingshuai Wang
- Rongrong Shen (ORCID: https://orcid.org/0000-0002-6721-4359)
Institutions
- International Peace Maternity & Child Health Hospital (CN)
- Shanghai East Hospital (CN)
- Shanghai Sixth People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1586877
- Citations
- 2
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59